R&D
R&D
Present) YEPBIO R&D Center Director
- Medi-helpline_R&D Center Director
- Formerly employed at: K-MFDS, SK Chemical,
Whan In Pharm., Korea Ginseng Corp
- Doctor of Pharmacy, Kyunghee University
- Technology Transfer Agent
COO In-Ho, Jung
Present) YEPBIO Outside Director
Present) Professor, Sungkyunkwan University
Present) Adjunct Professor at Johns Hopkins
- Johns Hopkins University postdoctoral fellow
- University of Vienna, Ph.D.(Chemistry)
- Seoul National University College of Medicine,
Master of Science (Tumor Biology)
CTO Joo-Ho, Shin
CTO's Research Featured in Top-tier Scientific Journals
• Cell. 2011 Mar 4;144(5):689-702 Ph.D Joo-Ho Shin
• PNAS. 2015 Sep 15;112(37):11696-701. Ph.D Joo-Ho Shin
• Cell Rep. 2017 Jan 24;18(4):918-932. Ph.D Joo-Ho Shin
• Sci Transl med. 2021 Jul 28;13(604):eaax8891. Ph.D Joo-Ho Shin
• Brain. 2021 Dec 31;144(12):3674-3691. Ph.D Joo-Ho Shin
• Parkin dysfunction causes PARIS accumulation in the substantia nigra
• PARIS is a transcriptional repressor that inhibits PGC-1⍺, a mitochondrial regulator
• PARIS accumulation causes dopaminergic neuron death
1. The first pioneering discovery of PARIS and Parkinson's disease
PARIS(ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
This finding has led to a series of ongoing preclinical and clinical studies.
2.Our pipeline is supported by multiple follow-up studies.
• PARIS - PINK1 Relation
• PARIS - c-Abl Relation
• PARIS - NLRP3 Relation
• PARIS - a-synuclein Relation
Amid diverse causes lies a single convergence point : PARIS
'PARIS' inhibition = PD treatment